z-logo
open-access-imgOpen Access
Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease
Author(s) -
Jonathan R. Lindner,
Todd Belcik,
Michael E. Widlansky,
Leanne Harmann,
Matthew S. Karafin,
Nancy J. Wandersee,
Mäneka Puligandla,
Doneuberg,
Joel Linden,
Joshua J. Field
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0218783
Subject(s) - medicine , microcirculation , blood flow , cardiology , contrast enhanced ultrasound , perfusion , blood volume , vasodilation , ultrasound , anesthesia , pathology , radiology
In patients with sickle cell disease (SCD), poor outcome measures compromise the potential success of clinical trials. Contrast-enhanced ultrasound (CEUS) is a technique that can non-invasively quantify deep tissue microvascular blood flow. We tested the hypothesis that CEUS of forearm skeletal muscle could be used to: 1) assess microvascular abnormalities that occur during vaso-occlusive crisis; and 2) test new therapies for SCD that are targeted to improving the status of the microcirculation. We performed a prospective study, CEUS perfusion imaging of resting forearm muscle was performed in adults with SCD: 1) during and after a pain episode, and 2) before, during, and after a 24-hour infusion of the investigative agent, regadenoson, an adenosine A 2A agonist. CEUS destruction-replenishment time-intensity data were analyzed to measure microvascular blood flow, as well as its components, microvascular blood volume and flux rate. Serial CEUS measurements were obtained in 32 adults with SCD. For the studies during crisis, there was a 30% reduction in microvascular blood flow compared to steady-state (p = 0.031), a reduction that was largely due to microvascular flux rate. For the regadenoson group, a non-significant 25% increase in flux rate and 9% increase in microvascular blood flow compared to baseline were detected during infusion. In a study of adults with SCD, CEUS detected changes in microvascular blood flow associated with vaso-occlusive crises. No changes were found during an infusion of the adenosine A 2A agonist, regadenoson. This study provides preliminary evidence that CEUS could detect blood flow changes consistent with SCD physiology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here